

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Yuji YAMAZAKI et al.
Title: ANTIBODY AGAINST FIBROBLAST GROWTH FACTOR-23
Appl. No.: Not yet assigned
Int'l Appln. No: PCT/JP03/00017
Int'l Filing Date: January 6, 2003
Examiner: Not yet assigned
Art Unit: Not yet assigned

PETITION TO ACCEPT COLOR PHOTOGRAPHS UNDER 37 CFR 1.84

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 CFR 1.84(a)(2), Applicants petition for the acceptance of Figs. 15, 16A, 28, (color photographs) to be entered in the above-captioned application.

In support thereof, Applicants submit:

- I) A fee in the amount of \$130.00 as is set forth under 37 CFR 1.17(h);
- II) Three (3) sets of Figs. 15, 16A and 28 (in color);
- III) A black and white photocopy that accurately depicts, to the extent possible, the subject matter illustrated in the color drawing; and
- IV) An amendment to the specification indicating that the application contains color photos.

07/07/2004 GFREY1 00000119 10500296

04 FC:1460

130.00 0P

REMARKS

The attached color photographs, Figure 15, shows the results of detecting the presence of FGF-23 protein in tumor tissues extracted from patients with neoplastic osteomalacia by immunohistochemical staining.

The attached color photographs, Figure 16A, shows mouse FGF-23 RQ protein as detected by Western blotting using the 3C1E antibody, which was an anti-human FGF-23 monoclonal antibody, after separating purified mouse FGF-23RQ protein by SDS-polyacrylamide gel electrophoresis.

The attached color photographs, Figure 28, shows comparison of images of bone tissues of the proximal part of the tibia and the distal part of the femur of Hyp mice (Hyp/antibody) to which the mixture of antibodies (the 2C3B antibody and the 3C1E antibody) was repeatedly administered, with images of the tissues of the relevant regions of Hyp (Hyp/vehicle) and wild-type mice (Wild-type/vehicle) to which vehicles were administered. The extracted tibiae and femora were subjected to Villanueva Bone staining. They were resin-embedded, and then prepared to result in 5 μ m-thick nondecalcification sections. These samples were stained differently: osteoid is purple, calcified bone is light orange, low-calcified bone is light brown, and embedded cells are light purple under visible light.

Respectfully submitted,

Date 28 June 2004

By S. A. Bent

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768

10/500296

ANTI-ANTIBODY AGAINST FIBROBLAST
GROWTH FACTOR-23
Inventor(s): Yuji YAMAZAKI et al.
DOCKET NO.: 081356-0218



Fig. 15

Fig. 16A





Fig. 16B



Title: ANTIBODY AGAINST FIBROBLAST
GROWTH FACTOR-23
Inventor(s): Yuji YAMAZAKI et al.
DOCKET NO.: 081356-0218

10/20/2024

Fig. 28

